Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study.

Conran, Nicola; de Alvarenga Maximo, Claudia; Oliveira, Thais; Fertrin, Kleber Y; Lobo, Clarisse; Costa, Fernando F

Conran, Nicola; de Alvarenga Maximo, Claudia; Oliveira, Thais; Fertrin, Kleber Y; Lobo, Clarisse; Costa, Fernando F.

Conran N; Hematology Center, University of Campinas-UNICAMP, Campinas, SP, Brazil.
de Alvarenga Maximo C; Divisão de Hematologia, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (Hemorio), Rio de Janeiro, Brazil.
Oliveira T; Research Department, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (Hemorio), Rio de Janeiro, Brazil.
Fertrin KY; Hematology Center, University of Campinas-UNICAMP, Campinas, SP, Brazil.
Lobo C; Division of Hematology, University of Washington, Seattle, Washington, USA.
Costa FF; Research Department, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (Hemorio), Rio de Janeiro, Brazil.

Br J Haematol ; 199(1): 153-157, 2022 10.

Article en En | MEDLINE | ID: mdl-35834407

Asunto(s)

Anemia de Células Falciformes; Hidroxiurea; Anemia de Células Falciformes/complicaciones; Anemia de Células Falciformes/tratamiento farmacológico; Humanos; Hidroxiurea/efectos adversos; Dolor/tratamiento farmacológico; Dolor/etiología

Palabras clave

clinical trial; hydroxycarbamide; inflammation; sickle cell disease; vaso-occlusive crisis

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hidroxiurea / Anemia de Células Falciformes Tipo de estudio: Clinical_trials / Etiology_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google